Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Director Mansoor Raza Mirza sold 2,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $12.00, for a total value of $24,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Mansoor Raza Mirza also recently made the following trade(s):

  • On Friday, September 15th, Mansoor Raza Mirza sold 2,882 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $11.00, for a total value of $31,702.00.
  • On Monday, September 11th, Mansoor Raza Mirza sold 118 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $11.00, for a total value of $1,298.00.

Karyopharm Therapeutics Inc. (NASDAQ KPTI) traded down 0.93% during trading on Wednesday, hitting $11.67. The stock had a trading volume of 100,192 shares. The firm’s market cap is $550.10 million. The firm’s 50 day moving average is $10.13 and its 200 day moving average is $9.84. Karyopharm Therapeutics Inc. has a 1-year low of $6.27 and a 1-year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. During the same period in the previous year, the company earned ($0.84) earnings per share. The firm’s revenue was down 95.0% compared to the same quarter last year. On average, analysts anticipate that Karyopharm Therapeutics Inc. will post ($2.67) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Karyopharm Therapeutics Inc. (KPTI) Director Mansoor Raza Mirza Sells 2,000 Shares” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/04/karyopharm-therapeutics-inc-kpti-director-mansoor-raza-mirza-sells-2000-shares.html.

Several large investors have recently made changes to their positions in KPTI. Vanguard Group Inc. lifted its position in shares of Karyopharm Therapeutics by 31.1% in the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after buying an additional 384,658 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Karyopharm Therapeutics by 915.0% in the first quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock worth $5,400,000 after buying an additional 379,127 shares during the last quarter. Iguana Healthcare Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the first quarter worth about $3,531,000. Candriam Luxembourg S.C.A. lifted its position in shares of Karyopharm Therapeutics by 154.7% in the second quarter. Candriam Luxembourg S.C.A. now owns 438,000 shares of the company’s stock worth $3,964,000 after buying an additional 266,000 shares during the last quarter. Finally, Palo Alto Investors LLC lifted its position in shares of Karyopharm Therapeutics by 6.4% in the first quarter. Palo Alto Investors LLC now owns 3,406,475 shares of the company’s stock worth $43,739,000 after buying an additional 206,079 shares during the last quarter. 58.97% of the stock is owned by institutional investors.

Several analysts have recently issued reports on the company. Cantor Fitzgerald restated a “buy” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, September 20th. Royal Bank Of Canada assumed coverage on Karyopharm Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $14.00 price objective on the stock. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 31st. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Thursday, July 6th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $15.67.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.